中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

免疫治疗在肝细胞癌中的应用价值

邹燕梅 袁响林

邹燕梅,袁响林. 免疫治疗在肝细胞癌中的应用价值[J]. 临床肝胆病杂志, 2021, 37(8): 1758-1760. DOI: 10.3969/j.issn.1001-5256.2021.08.004
引用本文: 邹燕梅,袁响林. 免疫治疗在肝细胞癌中的应用价值[J]. 临床肝胆病杂志, 2021, 37(8): 1758-1760. DOI: 10.3969/j.issn.1001-5256.2021.08.004
ZOU YM, YUAN XL. Application value of immunotherapy in hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(8): 1758-1760. DOI: 10.3969/j.issn.1001-5256.2021.08.004
Citation: ZOU YM, YUAN XL. Application value of immunotherapy in hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(8): 1758-1760. DOI: 10.3969/j.issn.1001-5256.2021.08.004

免疫治疗在肝细胞癌中的应用价值

DOI: 10.3969/j.issn.1001-5256.2021.08.004
基金项目: 

国家自然科学基金青年科学基金项目 81773231

详细信息
    通讯作者:

    袁响林,yuanxianglin@hust.edu.cn

  • 中图分类号: R735.7

Application value of immunotherapy in hepatocellular carcinoma

Funds: 

National Natural Science Foundation of China Young Scientist Fund 81773231

  • 摘要: 免疫治疗为肝细胞癌(HCC)患者迎来了曙光。目前HCC单用免疫治疗药物已初显疗效,靶向和免疫联合治疗方案在HCC转化治疗、围术期治疗中展现了巨大潜力,探讨HCC靶向免疫治疗,以及治疗评价、预测体系和安全性等问题,系统阐述免疫治疗在HCC中的应用价值及未来的探索方向。

     

  • [1] SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2] ZHENG RS, SUN KX, ZHANG SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008.

    郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008.
    [3] Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of primary liver cancer (2020 edition)[M]. Beijing: People's Medical Publishing House, 2020.

    中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020.
    [4] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [5] FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.
    [6] QIN S, REN Z, MENG Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470-2045(20)30011-5.
    [7] YAU T, PARK JW, FINN RS, et al. LBA38_PR-CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol, 2019, 30(Suppl 5): v874-v875.
    [8] KUDO M, IKEDA M, MOTOMURA K, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117[J]. J Clin Oncol, 2020, 38(4_suppl): 513. DOI: 10.1200/JCO.2020.38.4_suppl.513.
    [9] FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
    [10] XU J, SHEN J, GU S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571.
    [11] SUN HC, ZHU XD, HUANG C, et al. Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study[J]. J Clin Oncol, 2020, 38(15_suppl): e16610. DOI: 10.1200/JCO.2020.38.15_suppl.e16610.
    [12] KOROKI K, KANOGAWA N, MARUTA S, et al. Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma[J]. Liver Cancer, 2021. [Online ahead of print] DOI: 10.1159/000515552.
    [13] EXPOSITO MJJ, AKCE M, ALVAREZ JLM, et al. 209TiP-CA209-9DX: Phase Ⅲ, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablationp[J]. Ann Oncol, 2018, 29(Suppl 9): ix65.
    [14] KUDO M, MOTOMURA K, WADA Y, et al. Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: Results from the phase 1b VEGF liver 100 trial[J]. Liver Cancer, 2021, 10(3): 249-259. DOI: 10.1159/000514420.
    [15] PINTER M, JAIN RK, DUDA DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: A review[J]. JAMA Oncol, 2021, 7(1): 113-123. DOI: 10.1001/jamaoncol.2020.3381.
  • 加载中
计量
  • 文章访问数:  130
  • HTML全文浏览量:  22
  • PDF下载量:  92
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-05-28
  • 修回日期:  2021-05-28
  • 刊出日期:  2021-08-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回